Following the publication of the appeal decision for molnupiravir, remdesivir and tixagevimab plus cilgavimab for treating COVID-19, the next steps are:
Molnupiravir: Following discussions with the company, it has been agreed that to address the upheld appeal points, a new single technology appraisal (STA) will be planned into the work programme. NICE will not publish final guidance on molnupiravir until the STA reaches a conclusion. Further details regarding timings will be available in due course.
Remdesivir: Following discussions with the company, it has been agreed that the committee will consider additional evidence and modelling related to the upheld appeal points. The meeting is anticipated to take place towards the end of 2023.
Tixagevimab plus cilgavimab: Discussions are continuing with the company. It is anticipated that final draft guidance on tixagevimab plus cilgavimab will be available at the same time as it is available for remdesivir.